In sum, these data suggest that the activation of RIG‐I in ovarian tumors is paralleled by a distinct regulatory program involving various mechanisms and pathways, an effect that may limit the innate immune response to a level that no longer constraints, but rather supports, tumor growth. This evidence concerns the gene RIGI and ovarian neoplasm.